Good Evening Market Enthusiast,

While most of the market fought headwinds through October, one biotech name kept climbing. Quietly. Consistently. Relentlessly.

📊 It finished the month up 75%, breaking out from a multi-month base while the Nasdaq slid 1.6%.

The reason?

A cell therapy with numbers the CAR-T world hasn’t seen in years.

💡 92% response rate.
💡 Zero neurotoxicity.
💡 Single-day CRS window.

That’s not hype… that’s data.

This program just earned FDA RMAT designation, secured an $8M grant from the California Institute for Regenerative Medicine, and added Dr. Nancy T. Chang — the biotech legend behind Tanox — to its board.

Insiders hold 39% of the float and have been adding on the way up.

When that kind of alignment meets this kind of chart, attention follows fast.

Tomorrow at 8AM EST, we’re dropping the full breakdown — what’s driving this surge, where the data leads next, and why the setup into November looks this sharp.

💥 Set your alert — this one’s not waiting around.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Paid Promotion. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is fina.ncial advice. Momentum Media LLC is not an analyst, st.o.ck broker, fina.ncial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.